New Type 2 Diabetes Guidelines and the Trend toward Newer Pharmacological Treatment

The online educational activity contains video and slides from the Internal Medicine Section‘s Endocrinology, Diabetes, and Metabolism Symposium held on August 2, 2015 during the National Medical Association’s 2015 Annual Convention and Scientific Assembly in Detroit, MI. This activity was supported by educational grants from Boehringer-Ingelheim/Lilly, Sanofi, Merck & Co.


National Medical Association Annual Convention and Scientific Assembly, 2015

New Type 2 Diabetes Guidelines and the Trend toward Newer Pharmacological Treatment


Diabetes mellitus has an enormous health and social impact and its incidence is rising throughout the world as a result of unhealthy lifestyles. Recent reports show that 30% of individuals with type 2 diabetes remain undiagnosed and a significant number of those diagnosed have glycemia that is poorly controlled. In the last few years, advances in our understanding of the clinical management of diabetes and glucose homeostasis has ushered in a new era in the management of diabetes. Consequently, there have been updates in the clinical practice guidelines for the treatment of diabetes and several new anti-glycemic agents are now available to physicians for early aggressive control of diabetes to improve outcomes. The National Medical Association Internal Medicine Diabetes Seminar will provide health professionals with an up-to-date review of current recommendations regarding screening and treatment strategies for type 2 diabetes. 

Learning Objectives

At the conclusion of this educational seminar, participants should be able to:

  1. Understand how and who to screen for type 2 diabetes.
  2. Apply the new guidelines for achieving HbA1c goals through intensive therapy in patients with diabetes.
  3. Express why "personalized" or "tailored" glycemic targets according to patient clinical characteristics are being recommended by guidelines and scientific societies.
  4. Recognize the role of tight glucose control early in the course of diabetes with emphasis on strategies that minimize hypoglycemia.
  5. Realize the role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes.
  6. Enumerate the importance of newer once-weekly GLP-1 and insulin formulations to improve patient adherence.
  7. Understand the implication of recent major clinical studies such as Examine, SAVOR-TIMI 53 and TECOS.
  8. Be familiar with how to initiate insulin therapy including inhaled insulin in individuals with inadequate glycemic control on other therapies.
  9. Recognize the health benefits and phamacologic approaches to targeting weight loss in obese diabetic and non-diabetics.

Disclosures / Acknowledgement of Financial Support

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose any relevant financial relationships.  An individual has a relevant financial relationship if he or she (or spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.  As an accredited provider balance, independence, objectivity, and scientific rigor must be demonstrated in all educational activities.

The following faculty presenters and planners/managers have stated that they do not have financial relationships or relationships to products or devices with any commercial interests related to the content of this activity during the past 12 months:

Ayotunde Dokun, M.D., PhD

Anthony Cannon, M.D.

Sam Dagogo-Jack, M.D.

Colin Syphax

Chanda Nicole Holsey, DrPH, MPH


Disclosures of Commercial Relationships

The following have listed the entities with whom they have relationships, not necessarily conflicting:                                                                                                           

James Gavin, M.D.

Speaker’s Bureau/Consultant:  AstraZeneca and Janssen Pharmaceutics

Consultant:  NovoNordisk, Abbott Diabetes Care, Intarcia Pharmaceuticals

Kwame Osei, M.D,

Advisory Boards:  Merck & Co., and AztraZeneca

Rita Louard, M.D.

Speaker’s Bureau:  AztraZeneca

Rhonda Bentley-Lewis, M.D.

Consultant:  Sanofi and Merck, Sharp & Dohme

Research grant:  Novartis 


Continuing Education Credits

The National Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The National Medical Association designates this internet enduring activity for a maximum for 1 AMA PRA Category 1 Credit.  Physicians should claim credit commensurate with the extent of their participation in the activity.

Participants must achieve at least 80% correct in the post test evaluation to be awarded credit. 


September 15, 2016


The National Medical Association (NMA) and its staff and consultants, are not responsible for injury or illness resulting from the use of medications or modalities discussed during this educational activity. The NMA does not endorse the use of off-labeled medications. Speakers must identify off-labeled status of any pharmaceuticals mentioned in their lectures.


Sorry, no CME courses were found.